Dental Care Clinics in Bridgeton, NJ Accepting Medicare
5 Dental Care Clinics found. Showing 1 - 5
 Upper Deerfield Dental Center Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 233 Laurel Heights Dr, Bridgeton, NJ 08302 Phone: 856-455-7111 Fax: 856-451-7458 |
Mariana C Elwell Dds Fagd Pc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 6 Atlantic St, Bridgeton, NJ 08302 Phone: 856-455-4095 Fax: 856-455-5292 |
Boss Dentistry Llc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 553 Shiloh Pike, Bridgeton, NJ 08302 Phone: 856-451-9064 Fax: 856-451-8414 |
Qdc Of Bridgeton Llc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1117 Highway 77, Suite A, Bridgeton, NJ 08302 Phone: 732-750-0707 |
Bridgeton Dental Associates, Pa Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1055 N Pearl St, Bridgeton, NJ 08302 Phone: 856-455-7785 Fax: 856-451-0174 |
News Archive
Scientists have identified genes that promote the growth and recurrence of skin cancer
Dr. Andrzej Dlugosz and colleagues at the University of Michigan and the National Cancer Institute have examined the functions of the Hedgehog (Hh) signaling pathway in basal cell carcinoma, the most common form of cancer, and have uncovered a subset of tumor cells that are resistant to inhibition of the Hh pathway.
Amgen announces voluntary recall of certain lots of EPOGEN and PROCRIT
Amgen announced today that certain lots of EPOGEN® and PROCRIT® (Epoetin alfa) vials are being voluntarily recalled from specialty distributors, wholesalers, pharmacies and healthcare providers as a precaution. The product that is being recalled may contain extremely thin glass flakes (lamellae) that are barely visible in most cases. The lamellae result from the interaction of the formulation with glass vials over the shelf life of the product.
Businesses prepare for next phase of health law implementation
Large employers around the country are hard at work to meet requirements that take effect in 2015. Also, in health law-related coverage, a look at proposals for cheaper plans on the marketplaces.
Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it has initiated a controlled two-arm Phase 2b clinical study of Azixa (verubulin) as a front-line treatment for glioblastoma multiforme (GBM).
Myriad and Clovis ink deal on FDA-approved BRACAnalysis CDx test to identify patients with germline BRCA mutations for rucaparib treatment
Myriad Genetics, Inc. and Clovis Oncology, Inc. have announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis' PARP inhibitor, Rubraca. Financial terms of the deal were not disclosed.
› Verified 3 days ago